var data={"title":"Desmopressin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Desmopressin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5992?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">see &quot;Desmopressin: Drug information&quot;</a> and <a href=\"topic.htm?path=desmopressin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Desmopressin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112251\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hyponatremia (Noctiva nasal spray):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death. Desmopressin is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. Ensure serum sodium concentrations are normal before starting or resuming desmopressin. Measure serum sodium within 7 days and ~1 month after initiating therapy or increasing the dose and periodically during treatment. More frequently monitor serum sodium in patients &ge;65 years of age and in patients at increased risk of hyponatremia. If hyponatremia occurs, desmopressin may need to be temporarily or permanently discontinued.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157823\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>DDAVP;</li>\n      <li>DDAVP Rhinal Tube;</li>\n      <li>Noctiva;</li>\n      <li>Stimate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157824\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>DDAVP;</li>\n      <li>DDAVP Melt;</li>\n      <li>DDAVP Rhinyle;</li>\n      <li>Nocdurna;</li>\n      <li>Octostim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057762\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hemostatic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hormone, Posterior Pituitary</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasopressin Analog, Synthetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057755\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">see &quot;Desmopressin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing presented is in mcg, mg, and mL (dependent upon product formulation); use extra precaution to verify product formulation and dosing units. Intranasal dosage forms have unique concentrations and indications for use and should not be used interchangeably; use in pediatric patients is contraindicated for some products (eg, Noctiva); consult product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes insipidus: Note:</b> Fluid restriction should be observed in these patients; younger patients more susceptible to plasma osmolality shifts and possible hyponatremia. Dosing should be individualized to response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children &ge;4 years and Adolescents: Initial: 0.05 <b>mg</b> twice daily; titrate to desired response; optimal daily dose range: 0.1 to 0.8 mg/day in 2 to 3 divided doses; reported daily dose range: 0.1 to 1.2 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: DDAVP nasal spray, rhinal tube (100 mcg/mL nasal solution); <b>Note:</b> The nasal spray pump can only deliver fixed doses in 10 mcg (0.1 mL) increments; if doses other than this are needed, the rhinal tube delivery system is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months and Children: Initial: 5 mcg/day in 1 to 2 divided doses; usual range: 5 to 30 mcg/day (0.05 to 0.3 mL/day) in divided doses; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 5 to 40 mcg/day in 1 to 3 divided doses; usual adult dose is 20 mcg/day in 2 divided doses; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: No definitive dosing available. Adult dosing should not be used in this age group; adverse events such as hyponatremia-induced seizures may occur. Dose should be reduced. Some have suggested an initial dosage range of 0.1 to 1 mcg in 1 or 2 divided doses (Cheetham, 2002). Initiate at low dose and increase as necessary. Closely monitor serum sodium levels and urine output; fluid restriction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 2 to 4 mcg/day in 2 divided doses or one-tenth (<sup>1</sup>/<sub>10</sub>) of the maintenance intranasal dose; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A and von Willebrand disease (type 1; mild to moderate):</b> <b>Note:</b> Adverse events such as hyponatremia-induced seizures have been reported especially in young children with IV use (Das, 2005; Moln&aacute;r, 2005; Smith, 1989; Thumfart, 2005; Weinstein, 1989). Fluid restriction and careful monitoring of serum sodium levels and urine output are necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants &ge;3 months, Children, and Adolescents: 0.3 mcg/kg; if used preoperatively administer 30 minutes before procedure; may repeat dose if needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: Stimate (high concentration spray 1.5 mg/mL): Infants &ge;11 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;50 kg: 150 mcg (1 spray)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg: 300 mcg (1 spray each nostril)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Repeat use is determined by the patient's clinical condition and laboratory work; if using preoperatively, administer 2 hours before surgery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nocturnal enuresis: Note:</b> Intranasal formulations are not recommended for nocturnal enuresis treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children &ge;6 years and Adolescents: Initial: 0.2 mg once before bedtime; titrate as needed to a maximum of 0.6 <b>mg</b>; fluid intake should be limited to a minimum from 1 hour before desmopressin administration until the next morning, or at least 8 hours after administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes insipidus:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, SubQ: 2 to 4 mcg/day (0.5 to 1 mL) in 2 divided doses or one-tenth (<sup>1</sup>/<sub>10</sub>) of the maintenance intranasal dose. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal (100 mcg/mL nasal solution): 10 to 40 mcg/day (0.1 to 0.4 mL) divided 1 to 3 times daily; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover. <b>Note:</b> The nasal spray pump can only deliver doses of 10 mcg (0.1 mL) or multiples of 10 mcg (0.1 mL); if doses other than this are needed, the rhinal tube delivery system is preferred. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1 to 1.2 mg divided 2 to 3 times daily). Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nocturia: </b>Intranasal (0.83 mcg/0.1 mL and 1.66 mcg/0.1 mL nasal solution):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Not at risk for hyponatremia: 1.66 mcg in either the left or right nostril ~30 minutes before bed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">At risk for hyponatremia: 0.83 mcg in either the left or right nostril ~30 minutes before bedtime. After &ge;7 days, may increase to 1.66 mcg, if needed (provided the serum sodium is within the normal range during treatment with the 0.83 mcg dose). <b>Note:</b> The 0.83 mcg dose did not meet all prespecified efficacy endpoints in clinical trials but may have a lower risk of hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary nocturnal enuresis:</b> Oral: 0.2 mg at bedtime; dose may be titrated up to 0.6 mg to achieve desired response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A and mild to moderate von Willebrand disease (type 1): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.3 mcg/kg by slow infusion; if used preoperatively, administer 30 minutes before procedure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal (using high concentration spray 1.5 mg/mL): &lt;50 kg: 150 mcg (1 spray); &ge;50 kg: 300 mcg (1 spray each nostril); repeat use is determined by the patient's clinical condition and laboratory work. If using preoperatively, administer 2 hours before surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute: Use is contraindicated according to the manufacturer (except 1.5 mg/mL nasal spray); however, has been used in acute and chronic renal failure adult patients experiencing uremic bleeding or for prevention of surgical bleeding (Mannucci 1983; Watson 1984).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157804\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Nasal, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Noctiva: 0.83 mcg/0.1 mL (3.8 g); 1.66 mcg/0.1 mL (3.8 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 4 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 4 mcg/mL (10 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mcg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as acetate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 0.01% (5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP Rhinal Tube: 0.01% (2.5 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stimate: 1.5 mg/mL (2.5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (2.5 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 0.1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 0.1 mg [DSC], 0.2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg, 0.2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157789\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005940\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">see &quot;Desmopressin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">DDAVP and Minirin 5 mL bottles contain 50 sprays.</p>\n    <p style=\"text-indent:0em;\">Stimate 2.5 mL bottles contain 25 sprays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057765\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Ensure that nasal passages are intact, clean, and free of obstruction prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DDAVP (100 mcg/mL): Nasal pump spray: Delivers 0.1 mL (10 mcg); for doses &lt;10 mcg or for other doses which are not multiples, use rhinal tube. DDAVP nasal spray delivers fifty 10 mcg doses in the 5 mL bottle. For 10 mcg dose, administer in one nostril. Any solution remaining after 50 doses should be discarded. Pump must be primed prior to first use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DDAVP Rhinal tube (100 mcg/mL): Insert top of dropper into tube (arrow marked end) in downward position. Squeeze dropper until solution reaches desired calibration mark. Disconnect dropper. Grasp the tube <sup>3</sup>/<sub>4</sub>-inch from the end and insert tube into nostril until the fingertips reach the nostril. Place opposite end of tube into the mouth (holding breath). Tilt head back and blow with a strong, short puff into the nostril (for very young patients, an adult should blow solution into the child's nose). Reseal dropper after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noctiva: Do not shake. Prime before using for the first time by pumping 5 actuations into the air away from the face. Re-prime by pumping 2 actuations into the air if the product has not been used for more than 3 days. <b>Note:</b> 2 sprays of 0.83 mcg/0.1 mL are not interchangeable with 1 spray of 1.66 mcg/0.1 mL; do not administer 2 sprays of the 0.83 mcg/0.1 mL product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stimate (1.5 mg/mL): Nasal pump spray: Delivers 0.1 mL (150 mcg); for doses &lt;150 mcg, injection is recommended. Stimate nasal spray delivers twenty-five 150 mcg doses. For 150 mcg dose, administer in one nostril. Any solution remaining after 25 doses should be discarded. Pump must be primed prior to first use or if not used for &ge;1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablets: May administer with or without food. In adults, food may reduce/delay absorption although does not affect antidiuretic activity (Rittig 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes insipidus:</b> Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary nocturnal enuresis</b>: Minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central diabetes insipidus:</b> IV push or SubQ: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A and von Willebrand disease (type 1):</b> IV infusion: Infuse over 15 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157820\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DDAVP:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal spray: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Keep nasal spray in upright position.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rhinal Tube solution: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). May store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) for up to 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution for injection: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Avoid excessive heat. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">DDAVP Melt [Canadian product]: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F) in original container. Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nocdurna [Canadian product]: Store at 25&deg;C (77&deg;F). Excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture and light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noctiva: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); excursions permitted between 0&deg;C and 15&deg;C (32&deg;F and 59&deg;F). Keep nasal spray in upright position. After opening, store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Discard 60 days after opening.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octostim [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal spray: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Store in upright position. Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution for injection: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze. Following dilution in NS may store at room temperature for up to 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stimate nasal spray: Store at room temperature not to exceed 25&deg;C (77&deg;F). Discard 6 months after opening bottle. Store bottle in upright position.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057764\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablets: Treatment of diabetes insipidus (FDA approved in ages &ge;4 years and adults); primary nocturnal enuresis (FDA approved in ages &ge;6 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment of diabetes insipidus (FDA approved in ages &ge;12 years and adults); control of bleeding in hemophilia A (with factor VIII levels &gt;5%) and mild to moderate type I von Willebrand disease (FDA approved in ages &ge;3 months and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nasal spray:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">DDAVP: Treatment of diabetes insipidus (FDA approved in ages &ge;3 months and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noctiva: Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (FDA approved in ages &ge;50 years)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stimate: Control of bleeding in hemophilia A (with factor VIII levels &gt;5%) and mild to moderate type I von Willebrand disease (FDA approved in ages &ge;11 months and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rhinal tube: Treatment of diabetes insipidus (FDA approved in ages &ge;3 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27867242\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Desmopressin may be confused with vasopressin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Desmopressin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older for the treatment of nocturia or nocturnal polyuria due to its high risk of causing hyponatremia; safer alternatives exist (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157874\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Decreased blood pressure, facial flushing, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, headache, nostril pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyponatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, gastrointestinal disease, nausea, sore throat</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum transaminases (transient; associated primarily with tablets)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Burning sensation at injection site, erythema at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Abnormal lacrimation, conjunctivitis, ocular edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, epistaxis, nasal congestion, nasal discomfort, nasopharyngitis, rhinitis, sneezing, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormality in thinking, agitation, anaphylaxis (rare), balanitis, cerebral thrombosis (acute), chest pain, diarrhea, drowsiness, dyspepsia, edema, eye pruritus, hypersensitivity reaction (rare), insomnia, localized warm feeling, myocardial infarction, pain, palpitations, photophobia, tachycardia, vomiting, vulvar pain, water intoxication, weight gain (edema)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157810\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to desmopressin or any component of the formulations; hyponatremia or a history of hyponatremia; moderate to severe renal impairment (CrCl &lt;50 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional product specific contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noctiva: Polydipsia; primary nocturnal enuresis; concomitant use with loop diuretics or glucocorticoids (inhaled or systemic); syndrome of inappropriate antidiuretic hormone (SIADH) secretion (known or suspected); illnesses that may cause fluid or electrolyte imbalance (eg., gastroenteritis, salt-wasting nephropathies, systemic infection); heart failure (NYHA Class II to IV); uncontrolled hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stimate: There are no contraindications listed in the Stimate prescribing information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Note: May not be applicable to all available dosage forms; refer to manufacturer labeling for further detail. Type 2B or platelet-type (pseudo) von Willebrand disease; habitual or psychogenic polydipsia, cardiac insufficiency or other conditions requiring diuretic therapy; nephrosis or any other condition associated with impaired water excretion, severe hepatic dysfunction; primary nocturnal enuresis; sodium losing conditions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157793\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Severe allergic reactions have been reported with desmopressin; anaphylactic reactions have only occurred rarely with IV and intranasal administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: May cause fluid retention, which can worsen underlying conditions susceptible to volume status. Use with caution in patients with NYHA Class I heart failure; some products are contraindicated in NHYA Class II to IV heart failure or uncontrolled hypertension. Some products are not recommended in patients at risk for increased intracranial pressure of those with a history of urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: <b>[US Boxed Warning]: Noctiva: </b><b>Desmopressin can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death. Desmopressin is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. Ensure serum sodium concentrations are normal before starting or resuming desmopressin. Measure serum sodium within 7 days and ~1 month after initiating therapy or increasing the dose and periodically during treatment. More frequently monitor serum sodium in patients &ge;65 years of age and in patients at increased risk of hyponatremia. If hyponatremia occurs, desmopressin may need to be temporarily or permanently discontinued</b>. Desmopressin use may rarely lead to hyponatremia with associated signs and symptoms (eg, nausea/vomiting, headache, depressed reflexes, disorientation, irritability, muscle weakness/spasms/cramps) and extreme decreases in plasma osmolality, resulting in seizures, coma, respiratory arrest, and death. Other risk factors for hyponatremia with desmopressin use include cystic fibrosis, renal impairment, heart failure, young age, advanced age, inappropriate high fluid intake, a higher than recommended dose, and concomitant use of medications known to either increase thirst or cause syndrome of inappropriate antidiuretic hormone secretion (SIADH). Fluid restriction during use is recommended. Fluid intake in the evening and nighttime hours should be moderated to decrease the risk of hyponatremia. Monitor for signs/symptoms of hyponatremia; more frequent monitoring is recommended for patients on concomitant medications that increase the risk of hyponatremia (eg, TCAs, SSRIs, NSAIDs, chlorpromazine, carbamazepine, thiazide diuretics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Severe hypotension may occur with rapid IV infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Acute cerebrovascular thrombosis and acute myocardial infarction have occurred (rare) with desmopressin injection; use with caution in patients predisposed to thrombus formation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Injection and intranasal desmopressin may cause a slight increase or transient decrease in blood pressure, and a compensatory increase in heart rate. Use with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polydipsia (habitual or psychogenic): Use with caution in patients with habitual or psychogenic polydipsia. Patients consuming excessive amounts of water are at greater risk of hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress states/febrile illness: Lack of therapeutic effect has been observed in patients who have been febrile or stressed for several days; monitor for continued efficacy if indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Primary nocturnal enuresis: When using desmopressin for primary nocturnal enuresis, treatment should be interrupted if the patient experiences an acute illness (eg, fever, recurrent vomiting or diarrhea), vigorous exercise, or any condition associated with an increase in water consumption to prevent hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; von Willebrand disease type 2B: Patients with type 2B von Willebrand disease requiring hemostasis should not be treated with desmopressin since may result in platelet aggregation, thrombocytopenia, and possibly thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Fluid intake should be adjusted downward in the elderly to decrease the possibility of water intoxication and hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Fluid intake should be adjusted downward in very young patients to decrease the possibility of water intoxication and hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intranasal: Consider alternative route of administration if changes in the nasal mucosa (scarring, edema) occur leading to unreliable absorption. Some patients may demonstrate a change in response after long-term therapy (&gt;6 months) characterized as decreased response or a shorter duration of response. Discontinue in patients with concurrent nasal conditions that may increase systemic absorption of desmopressin (eg, atrophy of nasal mucosa, acute or chronic rhinitis); may resume desmopressin when conditions resolve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablet: Patients should be instructed to restrict fluid intake from 1 hour before to 8 hours after taking desmopressin tablets. Consider alternative route of administration (IV or intranasal) with inadequate therapeutic response at maximum recommended oral doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855799\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The FDA has reviewed 61 postmarketing cases of hyponatremia-related seizures associated with the use of desmopressin acetate. Intranasal desmopressin was used in the majority of cases. Many of the patients were children being treated for primary nocturnal enuresis (PNE). An association with at least one concomitant drug or disease that also may cause hyponatremia and/or seizures was noted. As a result, intranasal desmopressin is no longer indicated for the treatment of PNE.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299137\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157798\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13212&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproMAZINE: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Nasal): May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Demeclocycline: May diminish the therapeutic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loperamide-Loperamide Oxide: May increase the serum concentration of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May diminish the therapeutic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157800\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5559903\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Anecdotal reports suggest congenital anomalies and low birth weight. However, causal relationship has not been established. Desmopressin has been used safely throughout pregnancy for the treatment of diabetes insipidus (Brewster 2005; Schrier 2010). The use of desmopressin is limited for the treatment of von Willebrand disease in pregnant women (NHLBI 2007). Desmopressin is not recommended for nocturia treatment during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057761\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\"> For all uses, fluid intake, urine volume, and signs and symptoms of hyponatremia should be closely monitored especially in high risk patient subgroups (eg, young children, elderly, patients with heart failure).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diabetes insipidus: Urine specific gravity, plasma and urine osmolality, serum electrolytes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nocturnal enuresis: Serum electrolytes if used for &gt;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemophilia A: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII antigen levels, aPTT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">von Willebrand disease: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand antigen levels, bleeding time </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157792\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic analogue of the antidiuretic hormone arginine vasopressin. In a dose dependent manner, desmopressin increases cyclic adenosine monophosphate (cAMP) in renal tubular cells which increases water permeability resulting in decreased urine volume and increased urine osmolality; increases plasma levels of von Willebrand factor, factor VIII, and t-PA contributing to a shortened activated partial thromboplastin time (aPTT) and bleeding time. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157809\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Antidiuretic: 15 to 30 minutes; Increased factor VIII and von Willebrand factor (vWF) activity (dose related): 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak effect: Antidiuretic: 1 hour; Increased factor VIII and vWF activity: 1.5 hours; Nocturia: 0.25 to 0.75 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Increased factor VIII and vWF activity: 30 minutes (dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak effect: 1.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral tablet: Antidiuretic: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak effect: 4 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Intranasal, Injection, Oral tablet: ~6 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Sublingual: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Intranasal: ~3.5%; Oral tablet: 5% compared to intranasal, 0.16% compared to IV</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 to 4 hours; Renal impairment: 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9769997\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">1 mcg of desmopressin acetate injection is approximately equal to 4 units of antidiuretic activity; desmopressin acetate injection has an antidiuretic effect about ten times that of an equivalent dose administered intranasally</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157813\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Noctiva Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.83 mcg/0.1 mL (3.8 g): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.66 mcg/0.1 mL (3.8 g): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DDAVP Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg/mL (1 mL): $89.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DDAVP Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (5 mL): $527.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DDAVP Rhinal Tube Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (2.5 mL): $299.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Desmopressin Ace Spray Refrig Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (5 mL): $246.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Desmopressin Acetate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg/mL (1 mL): $12.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Desmopressin Acetate Spray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (5 mL): $246.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Stimate Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg/mL (2.5 mL): $828.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (DDAVP Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $832.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $1,198.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Desmopressin Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $528.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $761.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157814\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adin (AU, NZ);</li>\n      <li>Adin Melt (AU);</li>\n      <li>Adiuretin SD (HU);</li>\n      <li>Adiuretin-SD (CZ, HN, PL);</li>\n      <li>D-VOID (IN);</li>\n      <li>DDAVP (BR, CL, IT);</li>\n      <li>DDAVP Desmopressin (PT);</li>\n      <li>Defirin (GR);</li>\n      <li>Denirin (KR);</li>\n      <li>Des-Press (LK);</li>\n      <li>Desmin (KR);</li>\n      <li>Desmogalen (DE);</li>\n      <li>Desmomelt (GB);</li>\n      <li>Desmop ODIFS Powder (KR);</li>\n      <li>Desmopresin DDAVP (AR);</li>\n      <li>Desmospray (GB, IE, PT);</li>\n      <li>Desmotab (GB, IE);</li>\n      <li>Desmotabs (DE);</li>\n      <li>Desonic (KR);</li>\n      <li>Deturine (KR);</li>\n      <li>Dinadom (AR);</li>\n      <li>Minirin (AT, AU, BG, CH, CN, CO, DE, DK, EC, EE, FI, FR, HR, HU, IL, IS, KR, LK, LT, LU, LV, MY, NO, NZ, PE, PH, PK, PT, PY, RU, SE, SG, SI, TR, TW);</li>\n      <li>Minirin DDAVP (AE, BH, CY, GR, HK, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, TH, YE);</li>\n      <li>Minirin Melt (AE, AU, CU, CY, EG, IL, KW, LB, PH, QA, SA, TH);</li>\n      <li>Minirin Nasal Spray (AU, NZ);</li>\n      <li>Minirinmelt (FR);</li>\n      <li>Minirinmelt OD (JP);</li>\n      <li>Miniryn (UA);</li>\n      <li>Minrin (BE, LU, NL);</li>\n      <li>Minurin (ES);</li>\n      <li>Nafiset (MX);</li>\n      <li>Noctisson (AE, BG, BH, EG, IQ, IR, JO, LY, OM, QA, SY, YE);</li>\n      <li>Nocutil (CH);</li>\n      <li>Nocutil Nasenspray (DE);</li>\n      <li>Octim (FR);</li>\n      <li>Octim Nasal Spray (GB);</li>\n      <li>Octostim (AE, AR, AT, AU, BH, CH, CL, CO, DE, EC, EE, EG, ES, FI, HK, HU, IL, IQ, IR, IS, KW, LT, LV, LY, MX, NL, NO, NZ, OM, QA, SE, SG, SY, YE);</li>\n      <li>Octostim Nasal Spray (KR);</li>\n      <li>Octostin (AR);</li>\n      <li>Oktostym (UA);</li>\n      <li>Ovea Odifs Powder (KR);</li>\n      <li>Pizzard (MX);</li>\n      <li>Presinex (BG, GB);</li>\n      <li>Uremin (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brewster UC and Hayslett JP, &quot;Diabetes Insipidus in the Third Trimester of Pregnancy,&quot; <i>Obstet Gynecol</i>, 2005, 105(5 Pt 2):1173-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/15863571/pubmed\" target=\"_blank\" id=\"15863571\">15863571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheetham T and Baylis PH, &quot;Diabetes Insipidus in Children: Pathophysiology, Diagnosis and Management,&quot; <i>Paediatr Drugs</i>, 2002, 4(12):785-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/12431131/pubmed\" target=\"_blank\" id=\"12431131\">12431131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Das P, Carcao M, and Hitzler J, &quot;DDAVP-Induced Hyponatremia in Young Children,&quot; <i>J Pediatr Hematol Oncol</i>, 2005, 27(6):330-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/15956888/pubmed\" target=\"_blank\" id=\"15956888\">15956888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP injection (desmopressin acetate) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP nasal spray (desmopressin acetate) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDVAP rhinal tube (desmopressin acetate) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP tablets (desmopressin acetate) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eller N, Kollenz CJ, and Hitzenberger G, &quot;A Comparative Study of Pharmacodynamics and Bioavailability of 2 Different Desmopressin Nasal Sprays,&quot; <i>Int J Clin Pharmacol Ther</i>, 1998, 36(3):139-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/9562229/pubmed\" target=\"_blank\" id=\"9562229\">9562229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eller N, Kollenz CJ, Bauer P, et al, &quot;The Duration of Antidiuretic Response of Two Desmopressin Nasal Sprays,&quot; <i>Int J Clin Pharmacol Ther</i>, 1998, 36(9):494-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/9760011/pubmed\" target=\"_blank\" id=\"9760011\">9760011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6401193\"></a>Mannucci PM, Remuzzi G, Pusineri F, et al, &quot;Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia,&quot; <i>N Engl J Med</i>, 1983, 308(1):8-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/6401193/pubmed\" target=\"_blank\" id=\"6401193\">6401193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moln&aacute;r Z, Farkas V, Nemes L, et al, &quot;Hyponatraemic Seizures Resulting From Inadequate Post-Operative Fluid Intake Following a Single Dose of Desmopressin,&quot; <i>Nephrol Dial Transplant</i>, 2005, 20(10):2265-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/16014348/pubmed\" target=\"_blank\" id=\"16014348\">16014348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &ldquo;The Diagnosis, Evaluation, and Management of von Willebrand Disease,&rdquo; NIH Publication No. 08-5832. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noctiva nasal spray (desmopressin acetate) [prescribing information]. Milford, PA: Serenity Pharmaceuticals LLC; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. <i>Clin Endocrinol (Oxf)</i>. 1998;48(2):235-241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/9579238/pubmed\" target=\"_blank\" id=\"9579238\">9579238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robson WL, Leung AK, and Norgaard JP, &quot;The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children With Nocturnal Enuresis,&quot; <i>J Urol</i>, 2007, 178(1):24-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/17574054/pubmed\" target=\"_blank\" id=\"17574054\">17574054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrier RW, &quot;Systemic Arterial Vasodilation, Vasopressin, and Vasopressinase in Pregnancy,&quot; <i>J Am Soc Nephrol</i>, 2010, 21(4):570-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/19959721/pubmed\" target=\"_blank\" id=\"19959721\">19959721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Gill JC, Ambruso DR, et al, &quot;Hyponatremia and Seizures in Young Children Given DDAVP,&quot; <i>Am J Hematol</i>, 1989, 31(3):199-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/2500851/pubmed\" target=\"_blank\" id=\"2500851\">2500851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stenberg A and L&auml;ckgren G, &ldquo;Desmopressin Tablets in the Treatment of Severe Nocturnal Enuresis in Adolescents,&rdquo; <i>Pediatrics</i>, 1994, 94(6 Pt 1):841-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/7970999/pubmed\" target=\"_blank\" id=\"7970999\">7970999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stimate (desmopressin acetate) [prescribing information]. King of Prussia, PA: CSL Behring LLC; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thumfart J, Roehr CC, Kapelari K, et al, &quot;Desmopressin Associated Symptomatic Hyponatremic Hypervolemia in Children. Are There Predictive Factors?&quot; <i>J Urol</i>, 2005, 174(1):294-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/15947670/pubmed\" target=\"_blank\" id=\"15947670\">15947670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watson AJ and Keogh JA, &quot;1-Deamino-8-d-Arginine Vasopressin (DDAVP): A Potential New Treatment for the Bleeding Diathesis of Acute Renal Failure,&quot; <i>Pharmatherapeutica</i>, 1984, 3(9):618-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/6728864/pubmed\" target=\"_blank\" id=\"6728864\">6728864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinstein RE, Bona RD, Altman AJ, et al, &quot;Severe Hyponatremia After Repeated Intravenous Administration of Desmopressin,&quot; <i>Am J Hematol</i>, 1989, 32(4):258-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-pediatric-drug-information/abstract-text/2816922/pubmed\" target=\"_blank\" id=\"2816922\">2816922</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13212 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F51112251\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F157823\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F157824\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057762\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057755\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157804\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F157789\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005940\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057765\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F157820\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057764\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27867242\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157874\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157810\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157793\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855799\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299137\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157798\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F157800\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5559903\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057761\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F157792\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F157809\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F9769997\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F157813\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F157814\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13212|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=desmopressin-drug-information\" class=\"drug drug_general\">Desmopressin: Drug information</a></li><li><a href=\"topic.htm?path=desmopressin-patient-drug-information\" class=\"drug drug_patient\">Desmopressin: Patient drug information</a></li></ul></div></div>","javascript":null}